Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy.
Fifteen healthy adult volunteers received in their drinking water a lower Escherichia coli phage T4 dose (10(3) PFU/ml), a higher phage dose (10(5) PFU/ml), and placebo. Fecal coliphage was detected in a dose-dependent way in volunteers orally exposed to phage. All volunteers receiving the higher phage dose showed fecal phage 1 day after exposure; this prevalence was only 50% in subjects receiving the lower phage dose. No fecal phage was detectable a week after a 2-day course of oral phage application. Oral phage application did not cause a decrease in total fecal E. coli counts. In addition, no substantial phage T4 replication on the commensal E. coli population was observed. No adverse events related to phage application were reported. Serum transaminase levels remained in the normal range, and neither T4 phage nor T4-specific antibodies were observed in the serum of the subjects at the end of the study. This is, to our knowledge, the first safety test in the recent English literature which has measured the bioavailability of oral phage in humans and is thus a first step to the rational evaluation of phage therapy for diarrheal diseases.
Nestlé Research Center, Nestec Ltd., Vers-chez-les-Blanc, CH-1000 Lausanne 26, Switzerland.
Anne
A
Bruttin
Harald
H
Brüssow
D000284:Administration, Oral; D000328:Adult; D017122:Bacteriophage T4 / Q000302:isolation & purification / Q000502:physiology*; D001691:Biological Therapy / Q000009:adverse effects*; D018592:Cross-Over Studies; D003967:Diarrhea / Q000382:microbiology / Q000628:therapy* / Q000821:virology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004926:Escherichia coli / Q000821:virology; D004927:Escherichia coli Infections / Q000382:microbiology / Q000628:therapy* / Q000821:virology; D005243:Feces / Q000821:virology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged